UCL is a founding partner along with the Medical Research Council, Cancer Research UK and the Wellcome Trust to establish the Francis Crick Institute, a new £650 million medical research centre to be based next to St Pancras railway station and planned to open in 2015. The Institute will be Europe’s leading centre for medical research and will undertake research using the latest technology to understand why disease develops and find new ways to prevent and treat illnesses such as cancer, heart disease and stroke, infections, and neurodegenerative diseases.
UCLPartners is one of the UK’s first internationally accredited Academic Health Science Centres (AHSC), and is an Academic Health Science Network (AHSN), established to harness academia to improve population health, in London, nationally and beyond. The AHSC brings together UCL with Queen Mary University of London, Great Ormond Street, Moorfields, Royal Free, Barts Health, and University College London Hospitals NHS Trusts. As an AHSN, UCLPartners embraces Clinical Commissioning Groups; acute, community and mental healthcare providers; industry; local government; independent/third sector providers of NHS care; and international academic and clinical partners, to subserve a population footprint of six million people. By pooling resources and expertise, researchers and health practitioners will enable new discoveries in basic science to be translated into treatments more quickly; delivering proven innovation into practice at scale, both to improve patient and population health outcomes, and to generate wealth for the nation.
UCL is academic partner in three of the 11 Biomedical Research Centres of the National Institute for Health Research - the UCL Hospitals Biomedical Research Centre, the Moorfields Eye Hospital/UCL Institute of Ophthalmology NIHR Biomedical Research Centre and the Great Ormond Street Hospital/UCL Institute of Child Health Biomedical Research Centre. The Centres are leaders in scientific translation of fundamental biomedical research into clinical research that benefits patients.
The NIHR Biomedical Research Units (BRUs) undertake translational clinical research in priority areas of high disease burden and clinical need – UCL hosts a UCLH/UCL Biomedical Research Unit in Dementia, and works closely with the Barts and The London NIHR Cardiovascular Biomedical Research Unit under the UCL Partners umbrella.
CASMI is the Centre for the Advancement of Sustainable Medical Innovation, a partnership between UCL and the University of Oxford, created to develop new models for medical innovation. The centre aims to address the issues that have led to current failures in the translation of basic bioscience into affordable and widely adopted new treatments.
The collaborative was established between UCL, UCL Partners, Yale University, Yale School of Medicine and Yale – New Haven Hospital. The scale of the collaboration is the largest in the history of both universities with the goal of accelerating the research process to gain measurable advances for society. In biomedical research this means a more rapid conversion of basic science into translational research into therapeutic benefits.
UCL is a founder member of the GMEC which brings together key players in biomedical research and patient care in five UK major centres (UCL, IC, KCL, Oxford and Cambridge) to strengthen the UK research landscape and to take on challenging problems in healthcare and drug discovery.
The Sainsbury Wellcome Centre is a partnership between the Gatsby Charitable Foundation and the Wellcome Trust to establish a new Research Centre in Neural Circuits and Behaviour. The location of the Centre within UCL brings many benefits due to the strength of UCL's neuroscience research community and its relationships with other medical research organisations in the local area. UCL and the funders already work together with great success - the Gatsby Computational Neuroscience Unit and the Wellcome Trust Centre for Neuroimaging at UCL are both world leaders in their fields.